Lycera
discovers and develops small-molecule immunomodulators for the treatment of autoimmune diseases and cancer... Read moreLycera
discovers and develops small-molecule immunomodulators for the treatment of autoimmune diseases and cancer... Read more
News
Oct 22, 2018
BioPortfolio
Lycera: Lycera Corp Pharmaceuticals Healthcare Deals and Alliances Profile Report Updated 24072018 Prices from USD $250
Oct 10, 2018
PharmiWeb
Lycera: Lycera Announces Presentations at the 2018 ESMO Congress for LYC-55716, a First-in-class RORgamma Agonist Candidate
Aug 04, 2018
BioPortfolio
Lycera: Lycera Corp Pharmaceuticals Healthcare Deals and Alliances Profile Report Updated 23042018 Prices from USD $250
May 16, 2018
ForImmediateRelease
Press Release: Lycera : Lycera Announces Publication of Preclinical Immuno-Oncology Research, Demonstrating that Treatment with RORgamma Agonists Enhances CAR T-Cell Anti-Tumor Activity and Persistence, Resulting in Long-Lasting Anti-Tumor Memory T-Cells in an In Vivo Mode
Apr 05, 2018
PharmiWeb
Lycera: Lycera to Present Clinical Results and Supporting Preclinical Data for First-In-Class RORgamma Agonist LYC-55716 at the 2018 AACR Annual Meeting
Jan 04, 2018
Reuters
Lycera: BRIEF-Lycera Corp Announces Initiation Of Phase 1b Study Of Novel Immuno-Oncology Candidate LYC-55716 In Combination With Pembrolizumab
Oct 29, 2017
BioPortfolio
Lycera: Lycera Corp Pharmaceuticals Healthcare Deals and Alliances Profile Report Updated 11102017 Prices from USD $250
Oct 19, 2017
PR Newswire
Press Release: Lycera : Lycera Announces Advancement of Novel Immuno-Oncology Candidate LYC-55716 RORgamma Agonist into Phase 2a
Sep 10, 2017
BioSpace
Lycera: Lycera Presents Encouraging Safety Results From Phase I ARGON Study Of LYC-55716 At The
May 31, 2017
BioPortfolio
Lycera: Lycera Corp Pharmaceuticals Healthcare Deals and Alliances Profile Updated 10052017 Prices from USD $250
Lycera Competitors
1
2
3
4
5
6
7
8